Peptides DB
Research-centric peptide and protocol reference hub
Study 17 of 18Tirzepatide literatureJournal of dentistry · RCT2026

Clinical performance of monolithic and veneered zirconia three-unit posterior FDPs: A five-year multicenter randomized controlled trial.

All three types of zirconia FDPs showed high survival rates over five years, but monolithic designs had no technical complications, unlike the veneered options.

Read at Journal of dentistryAdd to compare

Where it sits

this study against the rest of the tirzepatide corpus
2
Preclinical
12
Observational
1
Open-label
1
Randomised · this one
2
Reviews

Summary and findings

This study evaluated the clinical performance of monolithic, partially veneered, and fully veneered zirconia three-unit fixed dental prostheses (FDPs) over five years. Sixty-four patients were randomly assigned to each group, and survival rates were assessed along with technical and biological complications. Results indicated high survival rates across all groups, with specific complications noted in the veneered groups.

How much of this paper we could read: full text read (0.90). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Survival at 5 years was 94.7% for MONO-FDPs, 100% for FV-FDPs, and 100% for PV-FDPs.2026

Abstract

The authors’ words, as Journal of dentistry supplied them

<h4>Aim</h4>This randomized controlled clinical study compared monolithic, partially veneered, and fully veneered zirconia FDPs over a 5-year period with respect to survival, technical and biological complications, and patient-reported outcome measures (PROMs).<h4>Materials and methods</h4>Sixty-four patients requiring three-unit posterior FDPs were randomly allocated to monolithic (MONO-FDP), partially veneered (PV-FDP), or fully veneered (FV-FDP) groups. All FDPs were fabricated from 4 mol% Y₂O₃ partially stabilized zirconia (4Y-TZP). Follow-up examinations were conducted at baseline, 1, 3, and 5 years. Technical parameters were evaluated using modified USPHS criteria. Periodontal measurements (PPD, BOP, PI) and patient satisfaction were assessed at all time points.<h4>Results</h4>A total of 63 FDPs were evaluated at baseline, 57 at 3 years, and 54 at 5 years. Survival at 5 years was 94.7% for MONO-FDPs, 100% for FV-FDPs and 100% for PV-FDPs. Technical complications occurred exclusively in PV-FDP (33%) and FV-FDP (38%) groups and consisted of minor, polishable chipping; no chipping or fractures were recorded in MONO-FDPs (0%) with statistically significant difference between MONO-FDP and the other two groups (p ≤ 0.014). Biological parameters remained stable across all groups, with no significant differences in PPD, BOP, or PI. PV-FDPs and FV-FDPs tended to receive more favorable professional color ratings, whereas PROMs were similar among the groups.<h4>Conclusions</h4>All three FDP designs-monolithic, partially veneered, and fully veneered-fabricated from 4Y-TZP zirconia demonstrated excellent 5-year clinical performance. Technical complications were limited to PV- and FV-FDPs and consisted of minor chipping. Biological outcomes and patient satisfaction were similar across groups.<h4>Clinical significance</h4>The five-year outcomes suggest that veneered, partially veneered, and monolithic FDPs can be used with high clinical reliability; however, restorations incorporating veneering ceramic may present an elevated risk of ceramic chipping.

Elsewhere in the Tirzepatide corpus

BEvaluating the therapeutic impact of tirzepatide in people with partial lipodystrophy.The Journal of clinical endocrinology and metabolism · 2026 · Body weight reduced from 91.0 kg (IQR 75.0 - 106.0) to 82.8 kg (IQR 69.0 - 93.4; p<0.0001).HumanBTirzepatide and the risk of atherosclerotic cardiovascular events: population based cohort study.BMJ (Clinical research ed.) · 2026HumanBEarly changes in body composition with tirzepatide in adults with obesity: a real-world BIA study.Nutrition (Burbank, Los Angeles County, Calif.) · 2026 · n=51 · Body weight decreased by 8.75 kg (-8.18%, P < 0.001)HumanDTirzepatide and cardiovascular outcomes.BMJ (Clinical research ed.) · 2026BGenomic analyses identify nosocomial transmission of ST23 carbapenem-resistant hypervirulent &lt;i&gt;Klebsiella pneumoniae&lt;/i&gt; mediated by a conjugative IncFII&lt;sub&gt;K2&lt;/sub&gt; NDM-1 plasmid.Virulence · 2026 · n=1069 · 0.37% ST23-K1 strains detected among 1069 CRKP bloodstream isolates.HumanDSerious acute biliary reporting with glucagon-like peptide-1-based therapies versus sodium-glucose cotransporter-2 inhibitors in type 2 diabetesbiorxiv-preprint · 2026 · 1.36 reporting odds ratio (95% CI 1.06-1.75; P = 0.013)review